Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.
22C3 PD-L1 expression
Cancer genome alterations
Epstein–Barr virus
Metastatic gastric cancer
Mismatch repair
Journal
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
ISSN: 1436-3305
Titre abrégé: Gastric Cancer
Pays: Japan
ID NLM: 100886238
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
27
03
2018
accepted:
29
05
2018
pubmed:
3
6
2018
medline:
16
4
2019
entrez:
3
6
2018
Statut:
ppublish
Résumé
Recently, the U.S. Food and Drug Administration approved pembrolizumab for patients (pts) with PD-L1-positive metastatic gastric cancer (MGC) based on 22C3 immunohistochemistry (IHC) assay. However, little is known about detailed clinicopathological features of 22C3 PD-L1 expression in MGC. Pts with histologically confirmed MGC were eligible for this prospective observational study. PD-L1 expression (22C3) on tumor cell (TC) or immune cell (IC) and mismatch repair (MMR) were analyzed by IHC. Epstein-Barr virus (EBV) was detected by in situ hybridization. The expressions of tyrosine kinase receptors (RTKs) and cancer genome alterations were evaluated by IHC or next-generation sequencing. A total of 225 pts were analyzed in this study. PD-L1 expression on TC, PD-L1 on IC, MMR-deficient (D-MMR), and EBV positivity were identified in 8.4, 65.3, 6.2, and 6.2% cases, respectively. PD-L1 expression in TC was more frequently observed in pts with D-MMR (P < 0.001), PIK3CA mutation (P = 0.020), and KRAS mutation (P = 0.002), and PD-L1 on IC was associated with EBV positivity (P = 0.034), and lymph-node metastasis (P < 0.001). PD-L1 expression on either IC or TC was less frequently observed in pts with peritoneal metastasis and Borrmann Type 4. A significant association was not observed between PD-L1 expression and RTKs expression or presence of other gene alterations. PD-L1 expression on either TC or IC was not prognostic factor. 22C3 PD-L1 expression in MGC was associated with distinct clinicopathological features, but was not a prognostic factor.
Sections du résumé
BACKGROUND
Recently, the U.S. Food and Drug Administration approved pembrolizumab for patients (pts) with PD-L1-positive metastatic gastric cancer (MGC) based on 22C3 immunohistochemistry (IHC) assay. However, little is known about detailed clinicopathological features of 22C3 PD-L1 expression in MGC.
PATIENTS AND METHODS
Pts with histologically confirmed MGC were eligible for this prospective observational study. PD-L1 expression (22C3) on tumor cell (TC) or immune cell (IC) and mismatch repair (MMR) were analyzed by IHC. Epstein-Barr virus (EBV) was detected by in situ hybridization. The expressions of tyrosine kinase receptors (RTKs) and cancer genome alterations were evaluated by IHC or next-generation sequencing.
RESULTS
A total of 225 pts were analyzed in this study. PD-L1 expression on TC, PD-L1 on IC, MMR-deficient (D-MMR), and EBV positivity were identified in 8.4, 65.3, 6.2, and 6.2% cases, respectively. PD-L1 expression in TC was more frequently observed in pts with D-MMR (P < 0.001), PIK3CA mutation (P = 0.020), and KRAS mutation (P = 0.002), and PD-L1 on IC was associated with EBV positivity (P = 0.034), and lymph-node metastasis (P < 0.001). PD-L1 expression on either IC or TC was less frequently observed in pts with peritoneal metastasis and Borrmann Type 4. A significant association was not observed between PD-L1 expression and RTKs expression or presence of other gene alterations. PD-L1 expression on either TC or IC was not prognostic factor.
CONCLUSIONS
22C3 PD-L1 expression in MGC was associated with distinct clinicopathological features, but was not a prognostic factor.
Identifiants
pubmed: 29859006
doi: 10.1007/s10120-018-0843-9
pii: 10.1007/s10120-018-0843-9
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
69-76Références
Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5
pubmed: 17360651
Histopathology. 2008 Jun;52(7):797-805
pubmed: 18422971
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Cancer Discov. 2015 Jan;5(1):43-51
pubmed: 25358689
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Gastric Cancer. 2016 Jan;19(1):42-52
pubmed: 25424150
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Gastric Cancer. 2016 Apr;19(2):466-71
pubmed: 26210691
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Lancet. 2016 Apr 9;387(10027):1540-50
pubmed: 26712084
Gut. 2017 May;66(5):794-801
pubmed: 26801886
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Immunother Cancer. 2016 Dec 20;4:84
pubmed: 28018599
JAMA Oncol. 2017 Aug 1;3(8):1051-1058
pubmed: 28278348
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
J Natl Cancer Inst. 2018 Mar 1;110(3):316-320
pubmed: 29155997
Immunity. 2017 Dec 19;47(6):1083-1099.e6
pubmed: 29246442